This activity is provided by Med Learning Group.
This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.
Copyright © 2024 Med Learning Group. Built by Divigner. All Rights Reserved.
Updates in the Management of Agitation Associated with Dementia Due to Alzheimer’s Disease
Chapter 1: Chris and Pam’s Story
Chapter 2: Susana and Lola’s Story
Chapter 3: Shirley and Dorothy’s Story
Chapter 1: Chris and Pam’s Story
FACULTY
Alireza Atri, MD, PhD
Director, Banner Sun Health Research Institute
Banner Health
Sun City, AZ
Lecturer on Neurology, Center for Brain/Mind Medicine
Brigham and Women’s Hospital and Harvard Medical School
Boston, MA
PROGRAM OVERVIEW
This educational activity is designed to provide clinicians who manage patients with Alzheimer’s disease with up-to-date information on agitation in these patients, the impact of agitation on patient and caregiver quality of life, behavioral approaches to managing agitation, and new and investigational medical therapies.
TARGET AUDIENCE
This activity is designed to meet the educational needs of primary care clinicians, geriatricians, psychiatrists, and neurologists as well as patients and caregivers concerning the identification of agitation associated with Alzheimer’s disease and appropriate management strategies.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the pathophysiology of agitation in Alzheimer’s disease (AD), including changes in neurotransmitter levels, eg, norepinephrine, serotonin, and dopamine
- Evaluate best practices in screening to identify AD-related agitation
- Describe the pharmacologic profile of and clinical data for current and emerging agents for the management of AD-related agitation
- Recognize the impact agitation has on patient/caregiver quality of life
- Identify opportunities for caregivers to manage agitation in patients with AD-associated agitation
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Alireza Atri, MD, PhD | Dr. Atri discloses that he has served as a consultant for Acadia, Biogen, Eisai, Lundbeck, Novo Nordisk, Qynapse, and Roche/Genentech, Life Molecular, Merck, and Prothena. He has reported that he has received sponsored grant/research support paid to his institution from Alzheon, Athira Pharma, ATRI/USC, Arizona DHS, Eisai, Lilly, Life Molecular, Lundbeck, Merk, Noro Nordisk, Prothena, Vivoryon Therapeutics, Foundation for NIH, Gates Ventures, Washington University in St Louis, and NIA/NIH. He has provided presentations or lectures on behalf of and received travel or conference/meeting related support from the Alzheimer’s Association, Alzheimer’s Disease International (ADI), Acadia, Biogen, Eisai, and Lundbeck. He has received book royalties from Oxford University Press. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Debra Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager, for Med Learning Group, has nothing to disclose.
- Jacquelyn Sandfort, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: March 29, 2024
EXPIRATION DATE: March 29, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Chapter 2: Susana and Lola’s Story
FACULTY
Marc Agronin, MD
Chief Medical Officer
Frank C. and Lynn Scaduto MIND Institute and Behavioral Health
Miami Jewish Health
Miami, FL
PROGRAM OVERVIEW
This educational activity is designed to provide clinicians who manage patients with Alzheimer’s disease with up-to-date information on agitation in these patients, the impact of agitation on patient and caregiver quality of life, behavioral approaches to managing agitation, and new and investigational medical therapies.
TARGET AUDIENCE
This activity is designed to meet the educational needs of primary care clinicians, geriatricians, psychiatrists, and neurologists as well as patients and caregivers concerning the identification of agitation associated with Alzheimer’s disease and appropriate management strategies.
LEARNING OBJECTIVE
Upon the completion of this program, attendees should be able to:
- Recognize the impact agitation has on patient/caregiver quality of life
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Marc Agronin, MD | Dr. Agronin discloses that he is a consultant for Eli Lilly, Otsuka, and Corium. He is on the Speakers Bureau for Otsuka. He has conducted research for Neurim, Cassava, Otsuka, Cerevel, Karuna, Suven, True Binding, Eisai, Biogen, and Alzheon. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Debra Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager, for Med Learning Group, has nothing to disclose.
- Jacquelyn Sandfort, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: June 03, 2024
EXPIRATION DATE: June 03, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Chapter 3: Shirley and Dorothy’s Story
FACULTY
George T. Grossberg, MD
Henry & Amelia Nasrallah Endowed Professor
Director of Geriatric Psychiatry
Department of Psychiatry & Behavioral Neuroscience
Saint Louis University School of Medicine
St. Louis, MO
PROGRAM OVERVIEW
This educational activity is designed to provide clinicians who manage patients with Alzheimer’s disease with up-to-date information on agitation in these patients, the impact of agitation on patient and caregiver quality of life, behavioral approaches to managing agitation, and new and investigational medical therapies.
TARGET AUDIENCE
This activity is designed to meet the educational needs of primary care clinicians, geriatricians, psychiatrists, and neurologists as well as patients and caregivers concerning the identification of agitation associated with Alzheimer’s disease and appropriate management strategies.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the pharmacologic profile of and clinical data for current and emerging agents for the management of AD-related agitation
- Recognize the impact agitation has on patient/caregiver quality of life
- Identify opportunities for caregivers to manage agitation in patients with AD-associated agitation
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| George T. Grossberg, MD | Dr. Grossberg discloses that he is a consultant for Acadia, Axsome Therapeutics, Biogen, BioXcel Therapeutics, Eisai, Genentech, Karuna Therapeutics, Lundbeck, Otsuka, Roche, and Takeda. He is on Speakers Bureaus for Biogen, and Eisai. He provides safety monitoring for Anavex Life Sciences, EryDel, Merck, and Oligomerix. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Debra Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager, for Med Learning Group, has nothing to disclose.
- Jacquelyn Sandfort, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: June 28, 2024
EXPIRATION DATE: June 28, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
